Mylan Inc (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

57.24USD
26 Feb 2015
Change (% chg)

-- (--)
Prev Close
$57.24
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
--
52-wk Low
--

MYL.OQ

Chart for MYL.OQ

About

Mylan Inc. (Mylan) is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Company’s generic pharmaceutical business is conducted primarily in the United States and... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $21,146.46
Shares Outstanding(Mil.): 374.27
Dividend: --
Yield (%): --

Financials

  MYL.OQ Industry Sector
P/E (TTM): 24.37 38.99 40.21
EPS (TTM): 2.32 -- --
ROI: 8.79 17.01 16.34
ROE: 27.88 17.53 17.27
Search Stocks

Mylan buys female health businesses from Indian drugmaker

- Mylan Inc said it would buy Indian drugmaker Famy Care Ltd's female health businesses for about $750 million in cash and $50 million in contingent payments to expand its line of women's health products.

02 Feb 2015

UPDATE 1-Mylan buys female health businesses from Indian drugmaker

Feb 2 - Mylan Inc said it would buy Indian drugmaker Famy Care Ltd's female health businesses for about $750 million in cash and $50 million in contingent payments to expand its line of women's health products.

02 Feb 2015

Mylan buys female health businesses from Indian drugmaker

Feb 2 - Mylan Inc said it would buy Indian drugmaker Famy Care Ltd's female health businesses to expand its line of women's health products.

02 Feb 2015

EU approves Mylan purchase of Abbot generics, subject to conditions

BRUSSELS - The European Commission approved on Wednesday the acquisition of Abbot Laboratories' non-U.S. Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM) by the U.S. based producer of generic pharmaceuticals Mylan Inc, subject to conditions.

28 Jan 2015

EU mergers and takeovers (Jan 28)

BRUSSELS, Jan 28 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

28 Jan 2015

EU approves Mylan purchase of Abbot generics, subject to conditions

BRUSSELS - The European Commission approved on Wednesday the acquisition of Abbot Laboratories' non-U.S. Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM) by the U.S. based producer of generic pharmaceuticals Mylan Inc , subject to conditions.

28 Jan 2015

EU approves Mylan purchase of Abbot generics, subject to conditions

BRUSSELS, Jan 28 - The European Commission approved on Wednesday the acquisition of Abbot Laboratories' non-U.S. Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM) by the U.S. based producer of generic pharmaceuticals Mylan Inc, subject to conditions.

28 Jan 2015

Medicines Co wins patent infringement suit against Mylan

Oct 27 - A U.S. court ruled Mylan Inc infringed the Medicines Co's patent on its blood-clot-inhibitor Angiomax, according to a court filing on Monday.

27 Oct 2014

U.S. court upholds patents on Pfizer's cancer drug

- A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.

23 Oct 2014

U.S. court upholds patents on Pfizer's cancer drug

Oct 23 - A U.S. district court ruled in favor of Pfizer Inc in a patent lawsuit it filed against Mylan Inc alleging patent infringement on its cancer drug, Sutent, Pfizer said.

23 Oct 2014

Competitors

  Price Chg
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs3,278.05 +25.85
Johnson & Johnson (JNJ.N) $102.80 +1.59
Pfizer Inc. (PFE.N) $34.59 -0.07
Novartis AG (NOVN.VX) CHF97.45 -0.70
Merck & Co., Inc. (MRK.N) $58.96 +0.47
Roche Holding Ltd. (ROG.VX) CHF258.10 -0.90
Abbott Laboratories (ABT.N) $47.61 +0.21
Bayer AG (BAYGn.DE) €131.40 -0.60
Bayer AG (BAYE.F) -- --
GlaxoSmithKline plc (GSK.L) 1,538.32p -15.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks